From top an­a­lyst to CFO: Cowen’s Er­ic Schmidt leaps in­to the top ranks of biotech’s lat­est overnight sen­sa­tion

Arie Bellde­grun has long held VIP cre­den­tials at Cowen and Co. The in­vest­ment group helped take Bellde­grun’s com­pa­ny Kite pub­lic. And Er­ic Schmidt, their top biotech an­a­lyst, was an un­abashed sell-side cheer­leader vir­tu­al­ly every step of the risky way, as Kite steered their way through a piv­otal and his­toric CAR-T pro­gram — stand­ing toe-to-toe with No­var­tis as Juno stum­bled bad­ly. 

When Gilead came along with a $12 bil­lion buy­out of­fer at $180 a share, Cowen helped ad­vise the Kite chief.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER